Drug Trial Radar · NCT04422899
Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3
Actual
Start
Aug 28, 2020
Primary completion
Sep 29, 2021
Study completion Feb 28, 2022
Sponsor
- Lead sponsor
- AiViva BioPharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine safety, pharmacokinetics, and duration of effect of intravitreally administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
AIV007Drug
intravitreal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: approximately 224 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Salehi Retina Institute
Huntington Beach, California
Retina Research Institute of Texas
Abilene, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.